On Monday, Immunome Inc (NASDAQ: IMNM) was 3.91% up from the session before settling in for the closing price of $13.55. A 52-week range for IMNM has been $6.93 – $30.96.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
When this article was written, the company’s average yearly earnings per share was at 18.60%. With a float of $50.75 million, this company’s outstanding shares have now reached $60.42 million.
In an organization with 55 employees, it is important to assess its efficiency. In terms of profitability, gross margin is 88.22%, operating margin of -3134.4%, and the pretax margin is -3014.59%.
Immunome Inc (IMNM) Insider Updates
Also, it is sometimes useful to examine the sentiment of large-scale investors toward Immunome Inc stocks. The insider ownership of Immunome Inc is 18.69%, while institutional ownership is 82.31%. The most recent insider transaction that took place on Nov 21 ’24, was worth 630,263. In this transaction President and CEO of this company bought 66,057 shares at a rate of $9.54, taking the stock ownership to the 485,693 shares. Before that another transaction happened on Nov 22 ’24, when Company’s President and CEO bought 33,943 for $9.78, making the entire transaction worth $331,918. This insider now owns 519,636 shares in total.
Immunome Inc (IMNM) Performance Highlights and Predictions
According to the Wall Street analysts, stocks earnings will be around 18.60% per share during the next fiscal year.
Immunome Inc (NASDAQ: IMNM) Trading Performance Indicators
You can see what Immunome Inc (IMNM) is doing with its current performance indicators. In the most recent quarter, the stock posted a quick ratio of 6.17. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 87.27.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -8.12, a number that is poised to hit -0.66 in the next quarter and is forecasted to reach -3.00 in one year’s time.
Technical Analysis of Immunome Inc (IMNM)
Let’s dig in a bit further. During the last 5-days, its volume was 1.21 million. That was better than the volume of 0.78 million it reported in year-ago period. As of the previous 9 days, the stock’s Stochastic %D was 96.42%. Additionally, its Average True Range was 0.90.
During the past 100 days, Immunome Inc’s (IMNM) raw stochastic average was set at 65.18%, which indicates a significant decrease from 92.91% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 113.40% in the past 14 days, which was higher than the 74.23% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $12.32, while its 200-day Moving Average is $15.66. However, in the short run, Immunome Inc’s stock first resistance to watch stands at $14.49. Second resistance stands at $14.89. The third major resistance level sits at $15.32. If the price goes on to break the first support level at $13.66, it is likely to go to the next support level at $13.23. Assuming the price breaks the second support level, the third support level stands at $12.83.
Immunome Inc (NASDAQ: IMNM) Key Stats
There are 62,417K outstanding shares of the company, which has a market capitalization of 884.05 million. As of now, sales total 14,020 K while income totals -106,810 K. Its latest quarter income was 2,910 K while its last quarter net income were -47,100 K.
